Mechanisms in COPD compared with asthma

To discuss the similarities and differences in inflammation between chronic obstructive pulmonary disease (COPD) and asthma.

To consider the clinical relevance of these differences.

To speculate about the therapeutic implications of this basic research.

Summary

Both asthma and COPD are characterised by airway obstruction, which is variable and reversible in asthma but is progressive and largely irreversible in COPD. In both diseases, there is chronic inflammation of the respiratory tract, mediated by increased expression of multiple inflammatory proteins, including cytokines, chemokines, adhesion molecules, inflammatory enzymes and receptors. In both diseases, there are acute episodes or exacerbations, when the intensity of this inflammation increases. The similarity between these airway diseases prompted the suggestion in the 1960s that asthma and COPD are part of a spectrum of a common disease (chronic obstructive lung disease) and this came to be known as the "Dutch hypothesis". This was countered by the "British hypothesis", which maintained that these diseases were separate entities; the debate continues today, with evidence both for and against these two views [1, 2].
Despite the similarity of some clinical features of asthma and COPD, there are marked differences in the pattern of inflammation that occurs in the respiratory tract, with different inflammatory cells recruited, different mediators produced, distinct consequences of inflammation and differing responses to therapy (figure 1). In addition, the inflammation seen in asthma is mainly located in the larger conducting airways. Although small airways may also be involved in more severe disease, the lung parenchyma is not affected. By contrast, COPD predominantly affects the small airways and lung parenchyma, although similar inflammatory changes may also be found in larger airways [3, 4]. These differences in disease distribution may partly reflect the distribution of inhaled inciting agents, such as allergens in asthma and tobacco smoke in COPD.

In both diseases, different clinical phenotypes are recognised. Most patients with asthma are atopic (extrinsic asthma), but a few patients are nonatopic (intrinsic asthma) and these patients often have more severe disease [5]. There is a spectrum of asthma severity, which tends to be maintained throughout life [6]. Approximately 5% of patients have severe asthma that is difficult to control with maximal inhaler therapy. For these patients, new therapeutic approaches are needed. The main types of COPD are the development of small airway obstruction and emphysema, which can occur alone or together, but both involve progressive airflow limitation and are usually caused by tobacco smoke.

The differences in inflammation between asthma and COPD are linked to differences in the immunological mechanisms of these two diseases (figure 2). There have been several recent important advances in our understanding of the immunopathology of asthma and COPD [7]. T-cells play a crucial role in both asthma and COPD and it is now recognised that different subsets are involved in orchestrating inflammation in these two diseases, resulting in different inflammatory and structural consequences. B-cells also play an important role, although this remains poorly understood in COPD. The appreciation that similar immune mechanisms are involved in both asthma and COPD has important implications for the development of new therapies for these troublesome diseases.

**Inflammatory cells and mediators**

There are many differences between the types of inflammation that occur in the lungs in mild asthma and COPD, with a different range of inflammatory cells and mediators being implicated in each [8, 9]. However, many of the cytokines and chemokines that are secreted in both asthma and COPD are regulated by the transcription factor nuclear factor-κB, which is activated in airway epithelial cells and macrophages in both diseases and may have an important role in amplifying airway inflammation.

**Histopathology**

The histological appearance of the airways of asthmatic individuals is very different from the changes found in patients with COPD (table 1, figure 3). Bronchial biopsies from asthmatic subjects reveal an infiltration of eosinophils, activated mucosal mast cells at the airway surface and activated T-cells. Characteristic structural changes in asthma include collagen deposition under the epithelium, which is sometimes described as basement membrane thickening and is found in all patients, and thickening of the airway smooth muscle layer as a result of hyperplasia and hypertrophy, which is more commonly

---

1. Bronchial inflammation, fibrosis (chronic obstructive bronchiolitis)
2. Disrupted alveolar attachments (emphysema)
3. Mucus hypersecretion (lumenal obstruction)

1. Bronchoconstriction (mast cell mediators)
2. Airway oedema (mast cell mediators)
3. Inflammatory exudate (plasma exudation)

**Figure 1** Differences in airway obstruction between a) COPD and b) asthma.
Asthma feature: Mechanisms in COPD compared with asthma

**Figure 2**
Inflammatory and immune cells involved in a) asthma and b) COPD. a) Inhaled allergens activate sensitised mast cells by crosslinking surface-bound immunoglobulin (Ig)E molecules to release bronchoconstrictor mediators, including cysteinyl-leukotrienes (cys-LTs) and prostaglandin (PG)D₂. Epithelial cells release stem-cell factor (SCF), which is important for maintaining mucosal mast cells at the airway surface. Allergens are processed by myeloid dendritic cells, which are conditioned by thymic stromal lymphopoietin (TSLP) secreted by epithelial cells and mast cells to release CC-chemokine ligand (CCL)17 and CCL22, which act on CC-chemokine receptor (CCR)4 to attract T-helper (Th)2 cells. Th2 cells have a central role in orchestrating the inflammatory response in allergy through the release of interleukin (IL)-4 and IL-13 (which stimulate B-cells to synthesise IgE), IL-5 (which is necessary for eosinophilic inflammation) and IL-9 (which stimulates mast-cell proliferation). Epithelial cells release CCL11, which recruits eosiinophils via CCR3. b) Inhaled cigarette smoke and other irritants activate epithelial cells and macrophages to release chemotactic factors that attract inflammatory cells to the lungs, including CCL2, which acts on CCR2 to attract monocytes, CC-chemokine ligand (CCL)11 and CCL8, which act on CCR2 to attract neutrophils and monocytes (which differentiate into macrophages in the lungs) and CXCL9, CXCL10 and CXCL11, which act on CXCR3 to attract Th1 cells and type 1 cytotoxic T-cells (Tc1 cells). These cells, together with macrophages and epithelial cells, release proteases, such as matrix metalloproteinase (MMP)-9, which cause elastin degradation and emphysema. Neutrophil elastase also causes mucus hypersecretion. Epithelial cells and macrophages release transforming growth factor (TGF)-β, which stimulates fibroblast proliferation, resulting in fibrosis in the small airways.
seen in patients with severe asthma. Epithelial cells are often shed from patient biopsies compared with normal control biopsies, as they are friable and more easily detached from the basement membrane during the biopsy procedure. In addition, there is an increase in the number of blood vessels (angiogenesis) in response to increased secretion of vascular endothelial growth factor [10]. Mucus hyperplasia is commonly seen in biopsies from asthmatic patients, with an increase in the number of mucus-secreting goblet cells in the epithelium and an increase in the size of submucosal glands [11].

In bronchial biopsies, small airways and lung parenchyma from patients with COPD, there is no evidence for mast cell activation, but there is an infiltration of T-cells and increased numbers of neutrophils, particularly in the airway lumen [12]. Subepithelial fibrosis is not apparent, but fibrosis does occur around small airways and is thought to be a major factor that contributes to the irreversible airway narrowing characteristic of this disease [13]. Airway smooth muscle is not usually increased in COPD patients compared with normal airways, and airway epithelial cells may show pseudostratification as a result of chronic irritation from inhaled cigarette smoke or other irritants and the release of epithelial cell growth factors. As in asthma, there is mucus hyperplasia and increased expression of mucin genes in biopsies from patients with COPD [14]. A marked difference between COPD and asthma is the destruction of alveolar walls (emphysema) that occurs in COPD as a result of protease-mediated degradation of connective tissue elements, particularly elastin, and apoptosis of type I pneumocytes and possibly endothelial cells [15, 16].

In addition, the production of elastolytic enzymes, such as neutrophil elastase and particularly several matrix metalloproteinases (MMPs), is increased in the lungs of COPD patients [17], and there may be a reduction in the levels of antiproteases such as α1-antitrypsin, as seen in a rare form of emphysema caused by a congenital deficiency of α1-antitrypsin [18].

**Mast cells**

Mast cells play a key role in asthma through the release of several bronchoconstrictors, including histamine, which is preformed and stored in granules, and the lipid mediators leukotriene (LT)C4, LTD4 and LTE4 and prostaglandin D2, which are synthesised on mast-cell activation. The release of these mediators may account for the variable bronchoconstriction seen in asthma, as the mediators are released by various environmental triggers, such as allergens, and by an increase in osmolality as a result of increased ventilation during exercise. Mucosal mast cells are recruited to

---

**Table 1 Differences in histopathology between asthma and COPD airways**

<table>
<thead>
<tr>
<th></th>
<th>Asthma</th>
<th>COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mast cells</td>
<td>Increased and activated</td>
<td>Normal</td>
</tr>
<tr>
<td>Dendritic cells</td>
<td>Increased</td>
<td>Uncertain</td>
</tr>
<tr>
<td>Neutrophils</td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>Th2</td>
<td>Th1, Tc1</td>
</tr>
<tr>
<td>Epithelium</td>
<td>Often shed</td>
<td>Pseudostratified</td>
</tr>
<tr>
<td>Goblet cells</td>
<td>Increased</td>
<td>Increased</td>
</tr>
<tr>
<td>Airway smooth muscle</td>
<td>Increased</td>
<td>Increased</td>
</tr>
<tr>
<td>Airway vessels</td>
<td>Increased</td>
<td>Minimal increase</td>
</tr>
<tr>
<td>Fibrosis</td>
<td>Subepithelial</td>
<td>Peribronchiolar</td>
</tr>
</tbody>
</table>

**Th:** T-helper; **Tc1:** type 1 cytotoxic T-cells.

---

**Figure 3**

Contrasting histopathology of asthma and COPD. A small airway from a patient who died from asthma and a similarly sized airway from a patient with severe COPD are shown. There is infiltration of inflammatory cells in both diseases. The airway smooth muscle (ASM) layer is thickened in asthma but only to a minimal degree in COPD. The basement membrane (BM) is thickened in asthma due to collagen deposition (subepithelial fibrosis) but not in COPD, whereas in COPD collagen is deposited mainly around the airway (peribronchiolar fibrosis). The alveolar attachments are intact in asthma, but are disrupted in COPD as a result of emphysema. Images courtesy of J. Hogg (iCAPTURE Centre, St Paul’s Hospital, Vancouver, BC, Canada).
the surface of the airways by stem cell factor released from epithelial cells, which acts on KIT receptors expressed by the mast cells [19]. Mast cells also release cytokines that are linked to allergic inflammation, including interleukin (IL)-4, IL-5 and IL-13 [20]. The presence of mast cells in the airway smooth muscle has been linked to airway hyperresponsiveness in asthma [21], as patients with eosinophilic bronchitis have a similar degree of eosinophilic inflammation to that found in asthmatics and also have subepithelial fibrosis, but they do not show hyperresponsiveness, which is the physiological hallmark of asthma. By contrast, mast cells do not seem to play a role in COPD, which may explain the lack of variable bronchoconstriction in this disease.

**Granulocytes**

The inflammation that occurs in asthma is often described as eosinophilic, whereas that occurring in COPD is described as neutrophilic. These differences reflect the secretion of different chemoattractants in these diseases. In asthma, eosinophil chemotactic factors, such as CC-chemokine ligand (CCL)11 (also known as eotaxin-1) and related CC-chemokines, are secreted mainly by airway epithelial cells. The functional role of eosinophils in asthma is not clear and the evidence that links their presence to airway hyperresponsiveness has been thrown into question by the finding that administration of IL-5-specific blocking antibodies that markedly reduce the number of eosinophils in the blood and sputum does not reduce airway hyperresponsiveness or asthma symptoms [22, 23]. As discussed above, eosinophilic bronchitis is not associated with airway hyperresponsiveness, but subepithelial fibrosis does occur, which suggests a role for eosinophils in airway fibrosis. Interestingly, the presence of eosinophils seems to be a good marker of steroid responsiveness [24]. Neutrophils are increased in the sputum of patients with COPD and this correlates with disease severity [25]. The increase in neutrophils is related to an increase in the production of CXC-chemokines, such as CXC-chemokine ligand (CXCL)1 (also known as GROα) and CXCL8 (also known as IL-8), which act on CXC-chemokine receptor (CXCR)2 expressed predominantly on neutrophils.

**Macrophages**

Macrophage numbers are increased in the lungs of patients with asthma and COPD, but their numbers are far greater in COPD than in asthma. These macrophages are derived from circulating monocytes, which migrate to the lungs in response to chemoattractants such as CCL2 (also known as MCP1) acting on CC-chemokine receptor (CCR)2 and CXCL1 acting on CXCR2 [26]. There is increasing evidence that lung macrophages orchestrate inflammation in COPD through the release of chemokines that attract neutrophils, monocytes and T-cells and the release of proteases, particularly MMP9 [27]. The pattern of inflammatory cells found in the respiratory tract therefore differs between patients with asthma and those with COPD. Some of these contrasts may be explained by differences in the immunological mechanisms driving the two diseases.

**Immune responses**

The immune mechanisms that drive the different inflammatory processes of asthma and COPD are mediated by different types of immune cell, in particular by different T-cell subsets. An understanding of which immune cells are involved is now emerging and may lead to the development of new and more-specific therapies for airway diseases in the future (figure 2).

**T-cells**

In asthmatic patients, there is an increase in the number of CD4+ T-cells in the airways. These are predominantly T-helper (Th2) cells, whereas in normal airways Th1 cells predominate [28]. By secreting the cytokines IL-4 and IL-13, which drive immunoglobulin (Ig)E production by B-cells, IL-5, which is solely responsible for eosinophil differentiation in the bone marrow, and IL-9, which attracts and drives the differentiation of mast cells [29], Th2 cells have a central role in allergic inflammation and therefore their regulation is an area of intense research.

The transcription factor GATA3 (GATA-binding protein 3) is crucial for the differentiation of uncommitted naive T-cells into Th2 cells and it also regulates the secretion of Th2-type cytokines [30, 31]. Accordingly, there is an increase in the number of GATA3+ T-cells in the airways of asthmatic subjects compared with normal subjects [32, 33]. Following simultaneous ligation of the T-cell receptor and co-receptor CD28 by antigen-presenting cells, GATA3 is phosphorylated and activated by p38 mitogen-activated protein kinase. Activated GATA3 then translocates from the cytoplasm to the nucleus, where it activates gene transcription [34]. GATA3 expression in T-
cells is regulated by the transcription factor signal transducer and activator of transcription (STAT)6 via IL-4 receptor activation.

For Th1 cell differentiation and secretion of the Th1-type cytokine interferon (IFN)-γ, the crucial transcription factor is T-bet. Consistent with the prominent role of Th2 cells in asthma, T-bet expression is reduced in T-cells from the airways of asthmatic patients compared with nonasthmatic patients [35]. When phosphorylated, T-bet can associate with and inhibit the function of GATA3, by preventing it from binding to its DNA target sequences [36]. T-bet deficient mice show increased expression of GATA3 and production of Th2-type cytokines, confirming that T-bet is an important regulator of GATA3 [35]. GATA3 expression is also regulated by IL-27, a recently identified member of the IL12 family, which downregulates GATA3 expression and upregulates T-bet expression, thereby favouring the production of Th1-type cytokines, which then act to further inhibit GATA3 expression [37]. In contrast, GATA3 inhibits the production of Th1-type cytokines by inhibiting STAT4, the major transcription factor activated by the T-bet-inducing cytokine IL-12 [38]. Nuclear factor of activated T-cells is a T-cell-specific transcription factor and appears to enhance the transcriptional activation of GATA3 at the IL4 promoter [39]. Finally, IL-33, a newly discovered member of the IL1 family of cytokines, seems to promote Th2 cell differentiation by translocating to the nucleus and regulating transcription through an effect on chromatin structure [40], but it also acts as a selective chemoattractant of Th2 cells by binding to the surface receptor IL-1 receptor-like 1 (also known as ST2), which is specifically expressed by these cells [41]. In contrast to asthma, the CD4+ T-cells that accumulate in the airways and lungs of patients with COPD are mainly Th1 cells. Th1 cells express the chemokine receptor CXCR3 [42] and may be attracted to the lungs by the IFN-γ-induced release of the CXCR3 ligands CXCL9 (also known as MIG), CXCL10 (also known as IP10) and CXCL12 (also known as I-TAC), which are present at high levels in COPD airways [43, 44]. However, there is some evidence that Th2 cells are also increased in lavage fluid of patients with COPD [45], likewise, in patients with more severe asthma Th1 cells are activated, as well as Th2 cells [46], making the distinction between the Th cell patterns in these two diseases less clear.

Other subtypes of CD4+ T-cells that may play an important role in airway diseases are regulatory T-cells, which have a suppressive effect on other CD4+ T cells and may play a role in regulating Th2 cell function in asthma [28, 47]. There is evidence that the numbers of CD4+CD25+ regulatory T-cells that express the transcription factor forkhead box (FOX)P3 are reduced in individuals with allergic rhinitis (hayfever) compared with nonatopic individuals, and this may be important in enabling high numbers of Th2 cells to develop in allergic disease [48]. However, by contrast, asthmatic patients seem to have an increase in FOXP3-expressing regulatory T-cells compared with patients with mild asthma, at least among circulating cells [49]. Analysis of sputum from COPD patients suggests that the numbers of CD4+CD25+FOXp3+ regulatory T-cells are reduced, but similar changes are also seen in people who smoke that do not have airflow obstruction [50]. So the role of regulatory T-cells in asthma and COPD remains unclear and further research is therefore needed, particularly in defining the role of different types of regulatory T-cells [51].

Another subset of CD4+ T-cells, known as Th17 cells, has recently been described and shown to have an important role in inflammatory and autoimmune diseases [52, 53]. Little is known about the role of Th17 cells in asthma or COPD, but increased concentrations of IL-17 (the predominant product of Th17 cells) have been reported in the sputum of asthma patients [54]. IL-17A and the closely related cytokine IL-17F have been linked to neutrophilic inflammation by inducing the release of CXCL1 and CXCL8 from airway epithelial cells [55]. As well as IL-17, Th17 cells also produce IL-21, which is important for the differentiation of these cells and thus acts as a positive autoregulatory mechanism, but it also inhibits FOXP3 expression and regulatory T-cell development [56, 57]. Another cytokine, IL-22, is also released by these cells and stimulates the production of IL-10 and acute-phase proteins [58]. However, more work is needed to understand the role of Th17 cells in asthma and COPD, as they may represent important new targets for future therapies.

A subset of CD4+ T-cells termed invariant natural killer T (iNKT) cells, which secrete IL-4 and IL-13, has been shown to account for 60% of all CD4+ T-cells in bronchial biopsies from asthmatic patients [59], but this has been disputed in another study, which failed to show any increase in iNKT-cell numbers in bronchial biopsies, bronchoalveolar lavage or sputum of either asthma or COPD patients [60]. The role of iNKT cells in asthma is currently uncertain as there appears to be a discrepancy between data from
Inflammatory activation.

Th1 and Tc1 cells then stimulate emphysema. IFN-γ induces apoptosis of type 1 pneumocytes, thereby contributing to emphysema.

CXCR3 expressed on Th1 cells and CXCL11, which together act on Th1 cells and Tc1 cells to attract them into the lungs. Tc1 cells, through the release of perforin and granzyme B, induce apoptosis of type 1 pneumocytes, thereby contributing to emphysema. IFN-γ released by Th1 and Tc1 cells then stimulates further release of CXCR3 ligands, resulting in a persistent inflammatory activation.

**Figure 4**

CD8+ T-cells in COPD. Epithelial cells and macrophages are stimulated by IFN-γ to release the chemokines CXCL9, CXCL10 and CXCL11, which together act on the CXCR3 expressed by the Th1 and Tc1 cells to attract them into the lungs. Tc1 cells, through the release of perforin and granzyme B, induce apoptosis of type 1 pneumocytes, thereby contributing to emphysema. IFN-γ released by Th1 and Tc1 cells then stimulates further release of CXCR3 ligands, resulting in a persistent inflammatory activation.

**Asthma feature: Mechanisms in COPD compared with asthma**

**Dendritic cells**

Dendritic cells (DCs) have an important role in asthma as regulators of Th2 cells and in the presentation of processed peptides from inhaled allergens to Th2 cells [72]. They are not only involved in the initial sensitisation to allergens, but also in driving the chronic inflammatory response in the lungs and therefore provide a link between allergen exposure and allergic inflammation in asthma. The cytokine thymic stromal lymphopoietin (TSLP), which is secreted in large amounts by epithelial cells and mast cells of asthmatic patients [73, 74], may have a critical role in the maturation of myeloid DCs and the recruitment of Th2 cells in the airways by inducing the release of CCL17 (also known as TARC) and CCL22 (also known as MDC), which bind to CCR4 that is selectively expressed by Th2 cells [75].
Cigarette smoking is associated with an expansion of the DC population, with a marked increase in the number of mature DCs in the airways and alveolar walls of people who smoke [76]. The role of DCs in COPD is currently unclear as there are no obvious antigenic stimulants as there are in asthma, although cryoglycoprotein isolated from tobacco is known to have a powerful immunostimulatory effect. However, a recent electron microscopy study has demonstrated a decrease in DCs of the airways in patients with COPD who smoke compared with smokers without airway obstruction, suggesting that they do not play a key role in COPD [77]. Another study shows a clear increase in the numbers of DCs in COPD patients, indicating that they may play a role in linking innate and acquired immunity [78].

Similarities between asthma and COPD

Although the inflammatory and immune mechanisms of asthma and COPD described above are markedly different, there are several situations where they become more similar and the distinction between asthma and COPD becomes blurred (table 2).

Severe asthma

Although only about 5% of the asthmatic population develop severe disease, such cases account for over half of the healthcare spending in asthma and they are poorly controlled by currently available therapies [79]. The inflammatory pattern occurring in severe asthma becomes more similar to that occurring in COPD than in mild asthma, with increased numbers of neutrophils in the sputum together with increased amounts of CXCL8 and tumour necrosis factor [80], increased oxidative stress and a poor response to corticosteroids as is observed in patients with COPD (table 2). Moreover, whereas in mild asthma Th2 cells predominate, in more severe disease a mixture of Th1 and Th2 cells is present in bronchial biopsies, as well as more CD8+ T-cells and this more closely resembles the immune-cell infiltration seen in COPD [46, 64, 65]. The neutrophilic inflammation seen in cases of severe asthma may be induced by IL-17 production by Th17 cells, which induces the release of the neutrophilic chemokine CXCL8 from airway epithelial cells [54, 55]. A neutrophilic pattern of inflammation, with high levels of CXCL8, is also found in the sputum of asthmatic individuals who smoke [81]. Similar to patients with severe disease or COPD, these individuals also have a poor response to corticosteroids, even if given orally in high doses.

Reversible COPD

Approximately 10% of patients with COPD have a reversibility of bronchoconstriction, showing >12% improvement in lung function as assessed by forced expiratory volume in one second (FEV1), and therefore behave more like asthmatics. Furthermore, compared with most patients with COPD, these patients more frequently have eosinophils in their sputum, an increase in exhaled nitric oxide and respond better to corticosteroid treatment, all of which are features of asthma [82, 83]. It therefore seems likely that

| Table 2 | Comparison between asthma and COPD inflammation patterns |
|---|---|---|
| | Mild | Asthma | Exacerbation | Mild | COPD | Exacerbation |
| Neutrophils | 0 | ++ | +++ | ++ | +++ | ++++
| Eosinophils | + | ++ | +++ | 0 | 0 | +
| Mast cells | ++ | + | ? | 0 | 0 | ?
| Macrophages | + | + | ? | +++ | ++++ | +++
| Chemokines | CCL11 | CXCL8+ | CXCL8+ | CXCL8+ | CXCL8+ | CXCL8+++ |
| Cytokines | IL-4 | TNF-α | ? | TNF-α | TNF-α | TNF-α |
| | IL-5 | ? | ? | ? | ? | ? |
| Lipid mediators | LTC4+ | LTB4+ | LTB4+ | LTB4+ | LTB4+ |
| | PRO2+ | ? | ? | ? | ? |
| Oxidative stress | 0 | ++ | +++ | ++ | ++++ | +++
| Steroid response | +++ | ++ | + | 0 | 0 | 0

0: no response; ++++++: magnitude scale; ?: uncertain.
these patients have concomitant asthma and COPD.

**Acute exacerbations**

Acute exacerbations (worsening of symptoms) occur in patients with asthma and COPD, and are a major cause of patient suffering and medical expenditure [84, 85]. Exacerbations in asthmatic individuals are usually triggered by upper respiratory tract infections, such as with rhinoviruses, and less commonly by inhaled allergens and air pollutants, whereas exacerbations in patients with COPD are usually triggered by either bacterial or viral infections. In both diseases, exacerbations are associated with a further increase in airway inflammation, increased numbers of cells infiltrating the lungs and higher concentrations of inflammatory mediators than are present in the stable state. However, there may also be changes in the pattern of inflammation. In exacerbations of asthma triggered by viruses, there can be increases in the numbers of neutrophils, as well as of eosinophils [84], whereas in COPD exacerbations, particularly those due to viruses, there may be an increase in eosinophil numbers [86]. So, during episodes of disease exacerbation, the pattern of inflammation becomes similar in COPD and asthma.

**References**

29. Kay AB. The role of T lymphocytes in asthma. Chem Immunol Allergy 2006; 91: 59–75.


40. Carriere V, Roosel L, Ortega N, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA 2007; 104: 267-272.


Asthma feature: Mechanisms in COPD compared with asthma


